Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00072059
Recruitment Status : Completed
First Posted : November 6, 2003
Last Update Posted : July 18, 2013
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Ro 50-3821 may stimulate red blood cell production and treat anemia in patients who are receiving antineoplastic therapy for non-small cell lung cancer.

PURPOSE: This randomized phase II trial is studying six different regimens of Ro 50-3821 to compare how well they work in treating anemia in patients who are receiving antineoplastic therapy for stage IIIB or stage IV non-small cell lung cancer.


Condition or disease Intervention/treatment Phase
Anemia Lung Cancer Biological: methoxy polyethylene glycol epoetin beta Phase 2

Detailed Description:

OBJECTIVES:

Primary

  • Compare the hemoglobin dose response of anemic patients with stage IIIB or IV non-small cell lung cancer receiving antineoplastic therapy treated with 6 different regimens of Ro 50-3821.

Secondary

  • Compare the safety profile of these regimens in these patients.
  • Compare the pharmacokinetic profile of these regimens in these patients.
  • Determine additional pharmacodynamic characteristics of these regimens in these patients.

OUTLINE: This is a randomized, open-label, parallel, multicenter study. Patients are randomized to 1 of 6 treatment arms. In all arms, patients begin study therapy on the first day of a course of antineoplastic therapy.

  • Arm I: Patients receive a lower dose of Ro 50-3821 subcutaneously (SC) once weekly.
  • Arm II: Patients receive a medium dose of Ro 50-3821 SC once weekly.
  • Arm III: Patients receive a higher dose of Ro 50-3821 SC once weekly.
  • Arm IV: Patients receive a lower dose of Ro 50-3821 SC once every 3 weeks.
  • Arm V: Patients receive a medium dose of Ro 50-3821 SC once every 3 weeks.
  • Arm VI: Patients receive a higher dose of Ro 50-3821 SC once every 3 weeks. In all arms, treatment continues for 12 weeks in the absence of unacceptable toxicity.

Patients are followed at 1 week.

PROJECTED ACCRUAL: A total of 210 patients (35 per treatment arm) will be accrued for this study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: An Open Label, Randomized, Multicenter, Phase II Study To Determine Hemoglobin Dose Response, Safety And Pharmacokinetic Profile Of Ro 50-3821 Given Subcutaneously Once Weekly Or Once Every 3 Weeks To Anemic Patients With Stage IIIB or IV Non-Small Cell Lung Carcinoma Receiving Antineoplastic Therapy
Study Start Date : July 2003
Actual Study Completion Date : February 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia Lung Cancer





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed non-small cell lung cancer

    • Stage IIIB or IV
  • Currently receiving first- or second-line antineoplastic therapy (must be scheduled to receive therapy during the 12 weeks of study therapy)

    • Antineoplastic therapy may include single agent or combination chemotherapy, corticosteroids, or a combination of these agents
  • Hemoglobin no greater than 11 g/dL

    • Transfusion independent
  • No known primary or metastatic CNS malignancy

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • More than 6 months

Hematopoietic

  • See Disease Characteristics
  • Platelet count 50,000-500,000/mm^3
  • No functional iron deficiency* (e.g., transferrin saturation less than 20% OR serum ferritin less than 100 ng/mL)
  • No known hemolysis NOTE: *Concurrent iron supplementation to correct deficiency allowed

Hepatic

  • Not specified

Renal

  • Creatinine no greater than 2.5 mg/dL

Cardiovascular

  • No clinically significant hypertension

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other malignancy within the past 5 years except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix
  • No acute or chronic bleeding requiring therapy within the past 3 months (e.g., patients with anemia caused by gastrointestinal bleeding)
  • No known cyanocobalamin deficiency
  • No known folic acid deficiency
  • No acute infection or inflammatory disease (C-reactive protein greater than 50 mg/L)
  • No known resistance to epoetin administration
  • No newly diagnosed (i.e., within the past 6 months) or uncontrolled epilepsy

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • More than 8 weeks since prior recombinant human erythropoietin therapy or any other erythropoiesis-stimulating drugs

Chemotherapy

  • See Disease Characteristics

Endocrine therapy

  • See Disease Characteristics

Radiotherapy

  • More than 4 weeks since prior radiotherapy

Surgery

  • Not specified

Other

  • More than 4 weeks since prior red blood cell transfusion
  • More than 30 days since prior investigational drugs or regimens
  • No prior enrollment and randomization to this study
  • No other concurrent investigational drugs or regimens

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00072059


Locations
Layout table for location information
United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: John A. Glaspy, MD, MPH Jonsson Comprehensive Cancer Center

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00072059     History of Changes
Other Study ID Numbers: ROCHE-NA17101
UCLA-0303085
CDR0000335429 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: November 6, 2003    Key Record Dates
Last Update Posted: July 18, 2013
Last Verified: January 2005

Keywords provided by National Cancer Institute (NCI):
anemia
stage IIIB non-small cell lung cancer
stage IV non-small cell lung cancer
recurrent non-small cell lung cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Anemia
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Hematologic Diseases
Antineoplastic Agents